Canadian Pharma Chooses Thought Leader Select for COPD Key Opinion Leader Engagement Strategy

December 20, 2012 · Leave a comment

December 20, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a medical strategy engagement in pulmonology with a top Canadian biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating chronic obstructive pulmonary disorder (COPD), approached Thought Leader Select for support with scientific advisory boards and continuing health education (CHE) initiatives across multiple Canadian provinces.  Having already worked with Thought Leader Select to form rosters of key opinion leaders in Canadian rheumatology and oncology circles, the company will formulate its panel of key experts in pulmonology by deploying Thought Leader Select’s team to assess the skills and experiences of physician specialists across the country.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of these leading experts in multiple areas where they collaborate to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the nursing and pharmacy communities, and a suite of tools to promote collaborative work with KOLs.  Among these ... read more »

TAGS:                                                           

The Medical Science Liaison Society’s Samuel Dyer—The Thought Leader Select Interview, Part Two

October 30, 2012 · Leave a comment

Thought Leader Select is a company focused on driving industry collaborations among biopharmaceutical, medical device, and diagnostics companies with leading medical experts and centers of excellence, with the ultimate goals of these collaborations being two-fold in purpose:  better treatment options for patients and better outcomes for global public health.  As part of our company’s mission, we work with multiple organizations to promote best practices that deliver ethical, transparent interactions among these various healthcare constituencies.

One of these groups is the recently-launched Medical Science Liaison Society, a global Non-Profit organization being led by the Chairman of the Board, Dr. Samuel Dyer.  The MSL Society is filling a vital need for the expanding role of Medical Science Liaisons around the world, as they collaborate with KOLs, physicians, and other health care professionals to advance medical science together to improve the quality of life for patients everywhere.

Thought Leader Select’s Allison Murphy, a veteran MSL herself from her days working in the Endocrinology Medical Affairs unit at Eli Lilly and Company, recently sat down with Dr. Dyer to learn more about this emerging organization and the impact the MSL Society is having in promoting the role of Medical Science Liaisons in the pharmaceutical, biopharmaceutical, medical device, and diagnostics industries.

In ... read more »

TAGS:                                                                     

Top US Pharma Chooses Thought Leader Select for Obesity Centers of Excellence Initiative

October 18, 2012 · Leave a comment

October 18, 2012 (CHAPEL HILL, NC)  Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement focused on medical centers of excellence in obesity with a top U. S. biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating the condition of obesity, approached Thought Leader Select for support with a variety of collaborative efforts, including medical science liaison outreach to leading universities, medical schools, teaching hospitals, and specialty clinics in this area.  Having already worked with Thought Leader Select to form rosters of key opinion leaders in endocrinology, primary care, nursing, pharmacy, and long-term care in the treatment of type I and type II diabetes and obesity, the company has now chosen Thought Leader Select to pinpoint the leading centers of excellence in the treatment of obesity in the United States.

Known for the versatility of applications for its in-house research and analysis, Thought Leader Select’s research group will assess the skills and experience of selected centers, detailing the collaborative activities of leading physicians and other health care professionals, including registered nurses, physician assistants, nurse practitioners, clinical pharmacists, and medical researchers, the people who advance the science of medicine and patient care, through basic and clinical research, scientific journal ... read more »

TAGS:                                                                                       

Not Enough Doctors?

August 22, 2012 · Leave a comment

Industry Insights from Paul Meade, M.Sc, MPH

Recently, I read a Wall Street Journal op-ed piece titled “Why the Doctor Can’t See You” by John Goodman, President of the National Center for Policy Analysis.  The central point of Goodman’s piece suggests that under the Affordable Care Act the “demand for healthcare will increase dramatically,” and there simply won’t be enough physicians in the United States to provide all this care.

Really?

While the United States does rank 53rd out of 145 countries in physicians per capita, with 2.4 medical doctors for every 1000 people, our country ranks higher than Japan at 2.1 MDs/1000, Canada at 2.0, China at 1.4, and India at 0.6 (according to a World Health Organization report). The global average is 1.4 doctors per 1000 people. The highest doctors-per-capita healthcare systems are those in Cuba (6.7/1000) and Greece (6.2/1000).

What does all of this mean? Does this mean that Cuba and Greece have a much healthier population than the U.S.? Canada has a universal healthcare system, offering healthcare to everyone, at a per-capita rate of 2.0 doctors. Can Canada provide its citizens with adequate healthcare delivery? It can, and it does. Can Japan handle healthcare demand for its people with only 2.1 MDs per 1,000, especially given its aging population? I dare say that it can, and it will.

So, if ... read more »

TAGS:                                         

Global Pharmaceutical Company Tabs Thought Leader Select for Gastroenterology Key Opinion Leader Partnership

June 21, 2012 · Leave a comment

June 21, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in gastroenterology with a top 10 global biopharmaceutical company.

The company, part of a select group of global leaders in drug development for products treating exocrine pancreatic insufficiency (EPI), approached Thought Leader Select for support with scientific advisory boards in support of a new product initiative.  To meet the strategic needs of the company’s advisory board activities in support of the new treatment, Thought Leader Select will deploy its in-house research group for an assessment of community-based key opinion leaders in gastroenterology throughout the United States.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in multiple areas where they advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.

For the national assessment, the Thought Leader Select research group will collaborate with a team of national key opinion leaders in gastroenterology to identify community-based physicians for grassroots-level scientific advisory work. Thought Leader Select will combine the key opinion leader recommendations with the experience data to optimize a pool of leading physicians with broad representation across multiple geographic ... read more »

TAGS:                                             

Top 30 Global Biopharmaceutical Company Chooses Thought Leader Select for Blood Disorder KOL Partnership

June 14, 2012 · Leave a comment

June 14, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a global engagement in blood disorders with a top 30 global biopharmaceutical company.

The biopharmaceutical company, part of a select group of global leaders in drug development for a product in development to treat iron overload in the body, approached Thought Leader Select for support with its launch activities across multiple global markets.  To meet the strategic needs of the company’s pre-launch for a new blood disorders treatment, Thought Leader Select will deploy its in-house research group for an assessment of key opinion leaders in the area of chelation therapy.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following geographic areas:

  • United States
  • Europe
  • Japan
  • Pacific Rim
  • Middle East

For the global assessment, the Thought Leader Select research group will identify 100 physicians appropriate for compliant engagement in support of drug development for blood disorders.

In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought ... read more »

TAGS:                                                     

Corporate Responsibility at Thought Leader Select

May 2, 2012 · Leave a comment

By Brian Castle and Kristen Smithwick

At Thought Leader Select, we have the privilege of working with a group of people who are always mindful of our company’s place in the big world of healthcare. We view our mission as a simple one, and that is to go about our work in ways that will always ultimately promote better patient care and public health outcomes.

We collaborate, through a strategic approach, with a variety of partner companies in the healthcare space—companies developing and commercializing pharmaceuticals, biotech treatments, medical devices, and diagnostics—as well as thousands of thought leaders, key advisors, and medical centers of excellence across more than 18 therapeutic areas covering over 50 diseases and conditions that affect millions of people around the world.

This week, we are proud to launch a new expression of our company’s mission and what we see as our responsibility to our partners across healthcare and the patients we all serve. We are proud of our team’s heritage in multiple areas of healthcare—our people have led industry teams working in brand and product commercialization, predictive medicine, and strategic planning, and they have also performed critical research work and delivered clinical care to patients alongside leading physicians in many of the top medical centers on multiple continents.

On our new Our Mission and Responsibility page, you’ll see a ... read more »

TAGS:                                         

Top 10 Global Biopharmaceutical Company Tabs Thought Leader Select for Infectious Disease Partnership

April 26, 2012 · Leave a comment

April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.

The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market.  To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.

Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:

Gastroenterology

Hepatology

Infectious Disease

Internal Medicine

For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.

In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »

TAGS:                                                                           

Understanding the Sunshine Act—Part Two

April 10, 2012 · Leave a comment

Industry Insights from Kristen Smithwick

Last week proved to be another interesting week for the developing Sunshine Act. Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) sent a pivotal memo to Acting CMS Administrator Marilyn Tavenner. The senators urged the agency to publish a final rule no later than June 2012 and to respond to several questions related to implementation.

Senators Grassley and Kohl want the agency to begin gathering transparency data this year, and they’re not willing to give CMS any wiggle room for delays. To meet the senators’ timeline, CMS will need to address comments and recommendations from numerous interested parties, especially the Pharmaceutical Research and Manufacturers of America (PhRMA), the Advanced Medical Technology Association (AdvaMed), and the Biotechnology Industry Organization (BIO). We covered a number of areas questioned in Part 1 of this blog. In this post, we’ll mention just a few additional areas of concern.

Definition of Applicable Manufacturer and Separate vs. Consolidated Reporting – Questions and concerns abound when it comes to defining applicable manufacturers, especially as the definition impacts requirements for separate vs. consolidated reporting for entities with common ownership. The challenge for CMS will be to ensure the definitions of applicable manufacturers and common ownership are broad enough to meet the public’s demand for transparency, while being specific enough to protect the ... read more »

TAGS:                                                             

Understanding the Sunshine Act—Part One

March 27, 2012 · Leave a comment

Industry Insights from Kristen Smithwick

Albeit a bit late, the U. S.  Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on the Patient Protection & Affordable Care Act’s Physician Payments Sunshine Provision (also known as the “Sunshine Act”) to implement it as law.

CMS invited comments on the proposed rule through mid-February 2012, and a recent webcast, sponsored by PharmaLive’s Pharmalot, featured key facts and summaries of comments on the proposed rule. Working for a provider of research and consulting to the biopharmaceutical, medical device, and diagnostics industries on relationships with physicians and other health care providers, I enjoyed the opportunity to join the webcast, led by experts from Buchanan Ingersoll & Rooney, P.C., and am eager to share some of my key takeaways.

As mentioned in previous Thought Leader Select Blog posts, the Sunshine Act, as with many laws and regulations, is full of unintended consequences – some positive and some negative. Lance K. Stell, medical ethics teacher at Davidson College and Carolinas Medical Center, reports in his USA Today op-ed piece that the “Sunshine Act will cost far more than the $224 million estimated for just the first year of compliance” and that “the biggest cost will be the valuable, socially useful physician-industry collaborations that simply won’t occur.” Of course, the idea of ... read more »

TAGS:                                                       

Older posts »